Anti-npy and pyy antibodies and uses thereof
AssigneeGarvan Institute of Medical Research
InventorsMartijn Bijker, Herbert Herzog, Fabienne McKay, Romain Rouet, Peter Schofield, David Zahra, Daniel Christ
Life of this patent
Estimating the term…
Abstract
The present disclosure provides proteins comprising antibody variable regions that bind specifically to NPY and PYY and uses thereof and methods of treating or preventing cancer or inducing an immune response by inhibiting NPY and PYY.
Claims55
An isolated or recombinant neuropeptide Y (NPY) and peptide YY (PYY)-binding protein comprising an antibody variable region, wherein the protein specifically binds to NPY and PYY.
An isolated or recombinant neuropeptide Y (NPY) and peptide YY (PYY)-binding protein comprising an antibody variable region, wherein the protein specifically binds to NPY and PYY, wherein the protein binds to an epitope comprising the sequence QRY-amide (SEQ ID NO:
- 80) at its C terminus.
An isolated or recombinant neuropeptide Y (NPY) and peptide YY (PYY)-binding protein comprising an antibody variable region, wherein (i) the protein specifically binds to NPY and PYY;
- (ii) the protein neutralizes NPY and PYY signaling;
- and (iii) the protein does not significantly and detectably bind to any one or more of SEQ ID NOs:
- 5, 6, 22-37, 53-55, 57, 59, 60, 63-67, 70, 75, 76 or 77.
An isolated neuropeptide Y (NPY) and peptide YY (PYY)-binding protein comprising:
- (i) a heavy chain variable region (VH) comprising the CDRs of a VH comprising a sequence set forth in SEQ ID NO:
- 85 or 86;
- and
- (ii) a light chain variable region (VL) comprising the CDRs of a VL comprising a sequence set forth in SEQ ID NO:
- 87,
- wherein the VH and VL bind to form a Fv that specifically binds to NPY and PYY.
An isolated or recombinant NPY and PYY-binding protein comprising a heavy chain variable region (VH) comprising the complementarity determining regions (CDRs) of a VH comprising a sequence set forth in SEQ ID NO:
- 102 and a light chain variable region (VL) comprising the CDRs of a VL comprising a sequence set forth in SEQ ID NO:
- 106,
- wherein the VH and VL bind to form a Fv that specifically binds to NPY and PYY.
An isolated or recombinant NPY and PYY-binding protein comprising:
- (i) a heavy chain variable region (VH) comprising the complementarity determining regions (CDRs) of a VH comprising a sequence set forth in SEQ ID NO:
- 99 and a light chain variable region (VL) comprising the CDRs of a VL comprising a sequence set forth in SEQ ID NO:
- 103;
- (ii) a VH comprising the CDRs of a VH comprising a sequence set forth in SEQ ID NO:
- 100 and a VL comprising the CDRs of a VL comprising a sequence set forth in SEQ ID NO:
- 104;
- or
- (iii) a VH comprising the CDRs of a VH comprising a sequence set forth in SEQ ID NO:
- 101 and a VL comprising the CDRs of a VL comprising a sequence set forth in SEQ ID NO:
- 105;
- wherein the VH and VL bind to form a Fv that specifically binds to NPY and PYY.
An isolated or recombinant neuropeptide Y (NPY) and peptide YY (PYY)-binding protein comprising a heavy chain variable region (VH) comprising a sequence set forth in SEQ ID NO:
- 85 or 86 and/or a light chain variable region (VL) comprising a sequence set forth in SEQ ID NO:
- 87 or a chimeric, deimmunized, CDR grafted, humanized or synhumanized form thereof,
- wherein the VH and VL bind to form a Fv that specifically binds to NPY and PYY.
An isolated or recombinant NPY and PYY-binding protein comprising one of the following:
- (i) a heavy chain variable region (VH) comprising a sequence set forth in SEQ ID NO:
- 99 and/or a light chain variable region (VL) comprising a sequence set forth in SEQ ID NO:
- 103;
- (ii) a VH comprising a sequence set forth in SEQ ID NO:
- 100 and/or a VL comprising a sequence set forth in SEQ ID NO:
- 104;
- or
- (iii) a VH comprising a sequence set forth in SEQ ID NO:
- 101 and/or a VL comprising a sequence set forth in SEQ ID NO:
- 105.
A method of treating or preventing cancer in a subject, the method comprising inhibiting NPY and PYY signaling in cells of the subject.
A method for inducing or enhancing an immune response in a subject, the method comprising inhibiting NPY and PYY signaling in cells of the subject.
Dependencies are inferred from the claim text.